Sensei Biotherapeutics to Showcase Innovations at Key Events
![Sensei Biotherapeutics to Showcase Innovations at Key Events](https://investorshangout.com/images/blog/ihnews-Sensei%20Biotherapeutics%20to%20Showcase%20Innovations%20at%20Key%20Events.jpg)
Sensei Biotherapeutics to Present at Upcoming Conferences
BOSTON - Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a leading company in the clinical stage of immuno-oncology, focuses on developing advanced therapies for cancer patients. The company is excited to announce that its management will be presenting at notable conferences in the coming month.
Event Highlights
The first event is the H.C. Wainwright 26th Annual Global Investment Conference, where the company will hold a corporate presentation on September 9, 2024. This will take place at 7:00 a.m. ET and will be accessible virtually as well as in New York.
2024 Cantor Fitzgerald Global Healthcare Conference
Following that, Sensei Biotherapeutics will participate in the 2024 Cantor Fitzgerald Global Healthcare Conference with a fireside chat scheduled for September 18, 2024, at 2:30 p.m. ET, also in New York.
Webcasts and Replays
Both presentations will be available to stream on the Investors section of the Sensei Biotherapeutics website. For 90 days post-event, replays can be accessed, allowing individuals the opportunity to gain insights into the company's innovative approaches and product pipeline.
About Sensei Biotherapeutics
At the forefront of immuno-oncology, Sensei Biotherapeutics (Nasdaq: SNSE) is dedicated to revolutionizing therapy options through its proprietary TMAb™ (Tumor Microenvironment Activated biologics) platform. The platform is engineered to develop conditionally active therapeutics that target immunosuppressive signals or enhance immunostimulatory signals within the tumor microenvironment.
Key Therapeutics in Development
Among its leading investigational candidates is SNS-101, designed to specifically block the V-domain Ig suppressor of T cell activation (VISTA) within the low pH tumor environment. This approach capitalizes on the unique properties of cancer cells to selectively combat T cell inhibition. Additionally, Sensei is advancing SNS-102, a monoclonal antibody targeting VSIG-4, as well as SNS-103, aimed at counteracting CD39 with ecto-nucleoside triphosphate diphosphohydrolase-1 specificity. Another exciting candidate, SNS-201, combines a CD28 agonist with an anti-VISTA arm to create a bispecific antibody designed for enhanced therapeutic efficacy.
Stay Connected
For more information about the innovative work at Sensei Biotherapeutics and their range of cancer therapies, please visit their website and follow the company on various platforms including X @SenseiBio and LinkedIn.
Contact Information
Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com
Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
Frequently Asked Questions
What is Sensei Biotherapeutics focused on?
Sensei Biotherapeutics is concentrating on developing next-generation immuno-oncology therapies aimed at enhancing treatment options for cancer patients.
When will Sensei present at the H.C. Wainwright Conference?
Sensei will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 a.m. ET.
What is the TMAb™ platform?
The TMAb™ platform by Sensei is focused on creating therapeutics that activate or disable immune responses directly in the tumor microenvironment.
Can I watch the presentations later?
Yes, both presentations will be available as webcasts and can be replayed for up to 90 days after the events.
How can I stay updated on Sensei's activities?
You can follow Sensei Biotherapeutics on their website, X @SenseiBio, and LinkedIn for the latest news and updates.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Experience Romance at Fairmont Orchid Inspired by 'The Bachelorette'
- Binswanger Welcomes Brooke Oldt as Senior VP of Corporate Services
- Cetera Welcomes Experienced Advisors to Wealth Partners Team
- GlobalVetLink's Automation Tool Enhances Rabies Vaccine Management
- Randstad US Study: Political Conversations and Workplace Safety
- CIBC Mellon, UPP & IMCO to Host Investment Fund Conference
- Hackensack Meridian Health Foundation Gala Honors Eli Manning
- UK Investor Behavior: Shift from Stocks to Money Markets
- Apple's Anticipated 'Glowtime' Event to Unveil Innovations
- Rising Bankruptcy Filings in Commercial Sector Highlight Trends
- Metabolomics Technologies Market Set to Surge by 2034
- Brunswick Corporation Awarded Trustworthy Company Recognition
- Myosin's Innovative Marketing Platform Redefines Advertising Impact
- Goya Foods Launches GOYA® Cares Hydrate for Hope Campaign
- Acer Introduces Eco-Friendly Vero PD2 Series LED Projectors
- Tower Arch Capital Partners with ACS Manufacturing for Growth
- Winking Studios Unveils GenMotion.AI for 3D Animation Innovation
- Norfolk Southern Signs Tentative Agreements with SMART-TD Unions
- Wells Fargo Advises Investors to Buy Election Weakness
- Tech Stocks Struggle Amid Economic Growth Concerns
- Blue Circle Health Launches New T1D Program in Northern States
- West Shore Home Appoints Al Patel as New Chief Marketing Officer
- Digestion Resistant Maltodextrin Market Set for Remarkable Growth
- Mid-Atlantic BioTherapeutics and Accelero Unite for Drug Discovery
- Peptide Therapeutics Market to Reach USD 85.9 Billion by 2031
Recent Articles
- Volaris Announces August 2024 Traffic Outcomes: 87% Load Factor
- NCICU Direct Admission Program Revolutionizes College Access
- CHESS Health Unveils Companion App for Substance Use Support
- Expert Insights Unveiled for RBQMLive 2024 Event Success
- Cinnamon-Based Solution: A Game Changer for Wound Care
- GridGain to Showcase Real-Time Data Innovations at Conferences
- COVID-19 Therapeutics Market Expected to Surpass $16 Billion
- SYNEVIT® Revolutionizes Health Solutions with Innovative Supplements
- Honda Launches Funding Cycle for Community Organizations
- Palo Alto Networks Completes Acquisition of IBM's QRadar Assets
- 1win Token Debuts: A Game-Changer in Blockchain Ecosystem
- Checkpoint Therapeutics to Feature at Investment Conference
- Vivid Seats Partners with I Am Athlete for Media Breakthrough
- Professor Baliga Receives €1 Million Millennium Technology Prize
- Sensei Biotherapeutics to Showcase Innovations at Key Events
- Plus Therapeutics to Present at H.C. Wainwright Conference
- REV Group Reports Mixed Earnings, Shares Drop 12% After Guidance
- YolTech Therapeutics Secures FDA Designation for YOLT-203
- Perricone Farms Strengthens Portfolio with Natalie's Juice Merger
- U-tec Showcases Innovative Smart Home Solutions at IFA
- Grath's Strategic Expansion: New Office in the Middle East
- Bitfarms Addresses Riot's Claims Amid Strategic Growth Plans
- Captivision Partners with Mohegan INSPIRE for Entertainment Innovation
- Rinchem's Commitment to Sustainability: Science-Based Targets Approval
- Petri Plumbing Encourages Gen Z to Explore Skilled Trades Careers